Related references
Note: Only part of the references are listed.
Article
Immunology
Zachary A. Yetmar et al.
Summary: This study retrospectively reviewed SOT recipients who developed breakthrough COVID-19 after full vaccination. The results showed that breakthrough COVID-19 can still occur in SOT recipients after full vaccination, but they generally have acceptable outcomes. Anti-spike monoclonal antibody therapy for eligible SOT patients may help mitigate disease progression and improve outcomes.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Immunology
Bonnie Ann Sarrell et al.
Summary: Studies suggest that early intervention with monoclonal antibody treatment directed against the SARS-CoV-2 spike protein may reduce the risk of emergency department visits or hospitalization for COVID-19 in solid organ transplant recipients. Our experience indicates that monoclonal antibody treatment may provide favorable outcomes for mild to moderate COVID-19 in SOT recipients during the study period with available formulations and viral variants.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Immunology
Javier T. Solera et al.
Summary: In an organ transplant population, this study found that receiving >= 3 doses of mRNA vaccine and using monoclonal antibody within 7 days of symptom onset can protect against severe outcomes in patients with vaccine breakthrough COVID-19.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Germaine Wong et al.
Summary: Despite vaccination, VOC Omicron infections in kidney and kidney pancreas transplant recipients can be severe, with high hospitalization rates. The use of sotrovimab may help prevent hospitalization.
Article
Immunology
Olivia S. Kates et al.
Summary: The mortality rate among SOT recipients hospitalized for COVID-19 was 20.5%, with age and underlying comorbidities being the major drivers of mortality, rather than measures related to immunosuppression intensity.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Anil Gupta et al.
Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Amanda J. Vinson et al.
Transplantation Direct
(2021)
Article
Immunology
Ravindra Ganesh et al.
Summary: This study compared the outcomes of high-risk patients who received bamlanivimab and casirivimab-imdevimab, showing similarly low rates of all-cause and COVID-19-related hospitalizations. Factors associated with higher likelihood of hospitalization included chronic kidney, respiratory, and cardiovascular diseases, as well as immunocompromised status.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
M. Dougan et al.
Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Zachary A. Yetmar et al.
Summary: This study retrospectively reviewed solid organ transplant recipients who received monoclonal antibody treatment for COVID-19, showing favorable outcomes and minimal adverse effects in this patient population. Early administration of monoclonal antibody therapy appears to be more efficacious.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Zachary A. Yetmar et al.
Summary: Monoclonal antibody therapy for COVID-19 appears to be safe and effective with favorable outcomes in solid organ transplant recipients, with earlier administration associated with reduced hospitalizations. No episodes of rejection or anaphylaxis were reported.
OPEN FORUM INFECTIOUS DISEASES
(2021)
